Syndax Pharmaceuticals, Inc.
- SNDX
- NASDAQ
- Biotechnology
- Cancer Therapies (Menin Inhibitors)
- Clinical-Stage Biotech
$12.90
Today −5.49%Quote Oct 16, 2026, 08:00 PM UTC
−27.04%over the last month
Max drawdown −31.4%From 1-month high −31.4%3 months −42.1%
Our viewPro
The call stays with Pro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Market value
$1.15B
Quote Oct 16
Next earnings
Nov 2
Expected, not confirmed
Analyst target
$36.67
+184.3% from here
Floor
$11.61
10.0% below price
Where the price sits
22 analysts
Analyst range, low to high
$31.00$46.00
- Price $12.90
- Resistance $14.39
- Consensus $36.67
Analysts' average target sits about 184% higher.
The call stays with Pro
7 locked chapters- What to do with this namePro
- Why nowPro
- Why this stockPro
- Section write-upsPro
- Story timelinePro
- News briefPro
- Ask about SNDXPro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Log in — 14 days freeWhere the money comes from
Q2 2026 revenue $72.8M
- Product$54.7M75.1%
- Collaboration revenue$18.1M24.9%
Industry
Biotechnology
Employees
298
Founded
2005